MTOR and non-small cell lung carcinoma: Meanwhile, several other studies [5, 7, 8] investigated the efficacy of other irreversible pan-HER receptor family inhibitors, dacomitinib, neratinib, or neratinib combining with mTOR inhibitors in advanced NSCLC patients harboring HER2 mutations and showed a moderate response of 12%–21%.